Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 10/20 | 0.51 |
| ▸ | HIPK4 | Q8NE63 | 4/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.51 |
| ▸ | SRPK1 | Q96SB4 | 4/20 | 0.49 |
| ▸ | STK3 | Q13188 | 4/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.49 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.49 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.49 |
| ▸ | DYRK4 | Q9NR20 | 2/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
| ▸ | AKT2 | P31751 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 7/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29128671 | 0.88 | CLK4 (0.53) | CLK4HIPK4MAP4K4CSNK2A1SRPK1 | |
| SCHEMBL10327562 | 0.84 | TAS2R14 (0.49) | CLK4HIPK4MAP4K4CSNK2A1SRPK1 | |
| SCHEMBL18425134 | 0.84 | ACVR1 (0.49) | CLK4HIPK4MAP4K4CSNK2A1SRPK1 | |
| SCHEMBL2635287 | 0.80 | TAS2R14 (0.57) | CLK4HIPK4MAP4K4CSNK2A1SRPK1 | |
| SCHEMBL17609790 | 0.80 | TRPV3 (0.50) | CLK4HIPK4MAP4K4CSNK2A1ABL1 | |
| SCHEMBL5031654 | 0.79 | P2RX7 (0.53) | CLK4HIPK4MAP4K4CSNK2A1SRPK1 | |
| SCHEMBL29640129 | 0.79 | P2RX7 (0.53) | CLK4HIPK4MAP4K4CSNK2A1SRPK1 | |
| SCHEMBL13170010 | 0.79 | KDM4E (0.56) | CLK4HIPK4MAP4K4CSNK2A1SRPK1 | |
| SCHEMBL19520239 | 0.78 | CLK4 (0.52) | CLK4HIPK4MAP4K4CSNK2A1SRPK1 | |
| SCHEMBL2578961 | 0.77 | ALDH1A1 (0.71) | GRM5ALDH1A1GAAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| US-20110172237-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA UK LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
| WO-2009138707-A9 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009138707-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172237-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | CLK4 2215/4885HIPK4 1875/4885MAP4K4 2145/4885 |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM5 | CLK4 2573/4885HIPK4 2772/4885MAP4K4 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.